Outcomes of treatment of pediatric choroidal neovascularization with intravitreal antiangiogenic agents

The results of the KKESH international collaborative retina study group

Igor Kozak, Ahmad Mansour, Rocio I. Diaz, Jorge I. Calzada, Francesco Pichi, Vanessa Cruz-Villegas, Manuel Diaz-Llopis, Jay Chhablani, Mauricio Martinez-Cartier, Martin Meerhoff, William F. Mieler, J Fernando Arevalo, Eman Al Kahtani, Nicola Ghazi, Sawsan Nowilaty, Saba Al Rashaed, Hassan A. Al-Dhibi, Yahya A. Al-Zahrani, Vishali Gupta, Sultan Ahmad Al-Kahtani & 23 others Naif Abdullah Al-Marzoog, Abdullah Saad Al-Robaie, Sulaiman Al-Sulaiman, Abdulelah Al-Abdullah, Ahmad Al-Bar, Yousef Al-Dhafiri, Abdullah Al-Qahtani, Khalid Al-Rubaie, Saeed Al-Shahrani, Maha Al-Shehri, Muhammad Younis, Wilson Heriot, Anthony Hall, Friederike Mackensen, Focke Ziemssen, Emilie Mercé, Rajiv Anand, Hamid Ahmadieh, Jorge Mataix, Paolo Nucci, David Sarraf, Gian Paolo Giuliari, Thomas A. Albini

Research output: Contribution to journalArticle

Abstract

PURPOSE:: To evaluate safety and clinical results of intravitreal antiangiogenic agents for choroidal neovascularization in pediatric patients. METHODS:: Retrospective, multicenter, interventional case series. A total of 45 eyes of 39 pediatric patients with choroidal neovascularization of various etiologies were treated with intravitreal injection of antiangiogenic agents (1.25 mg per 0.05 mL of bevacizumab or 0.5 mg per 0.05 mL of ranibizumab). RESULTS:: There were 24 girls and 15 boys with group median age of 13 years (range, 3-17 years). Mean follow-up period was 12.8 months (range, 3-60 months). Median visual acuity in terms of logarithm of the minimum angle of resolution at presentation and last follow-up was 0.87 and 0.7, respectively (P = 0.0003). Mean and median number of injections received over the follow-up period was 2.2 and 1, respectively. At the last follow-up, 22 eyes (48%) gained more than 3 lines of vision and 27 eyes (60%) had final visual acuity 20/50 or better. Nine eyes (20%) did not improve and had severe vision loss (20/200 or worse). CONCLUSION:: Intravitreal antiangiogenic therapy for choroidal neovascularization in pediatric patients seems temporarily safe and effective in majority of affected eyes. Because of the rarity and character of this condition, it is unlikely that any clinical trials will soon take place to study this or other treatment option.

Original languageEnglish (US)
Pages (from-to)2044-2052
Number of pages9
JournalRetina
Volume34
Issue number10
DOIs
StatePublished - Oct 12 2014

Fingerprint

Choroidal Neovascularization
Angiogenesis Inhibitors
Retina
Pediatrics
Visual Acuity
Intravitreal Injections
Age Groups
Clinical Trials
Safety
Injections
Therapeutics

Keywords

  • antiangiogenic therapy
  • children
  • choroidal neovascularization

ASJC Scopus subject areas

  • Ophthalmology
  • Medicine(all)

Cite this

Outcomes of treatment of pediatric choroidal neovascularization with intravitreal antiangiogenic agents : The results of the KKESH international collaborative retina study group. / Kozak, Igor; Mansour, Ahmad; Diaz, Rocio I.; Calzada, Jorge I.; Pichi, Francesco; Cruz-Villegas, Vanessa; Diaz-Llopis, Manuel; Chhablani, Jay; Martinez-Cartier, Mauricio; Meerhoff, Martin; Mieler, William F.; Arevalo, J Fernando; Al Kahtani, Eman; Ghazi, Nicola; Nowilaty, Sawsan; Al Rashaed, Saba; Al-Dhibi, Hassan A.; Al-Zahrani, Yahya A.; Gupta, Vishali; Al-Kahtani, Sultan Ahmad; Al-Marzoog, Naif Abdullah; Al-Robaie, Abdullah Saad; Al-Sulaiman, Sulaiman; Al-Abdullah, Abdulelah; Al-Bar, Ahmad; Al-Dhafiri, Yousef; Al-Qahtani, Abdullah; Al-Rubaie, Khalid; Al-Shahrani, Saeed; Al-Shehri, Maha; Younis, Muhammad; Heriot, Wilson; Hall, Anthony; Mackensen, Friederike; Ziemssen, Focke; Mercé, Emilie; Anand, Rajiv; Ahmadieh, Hamid; Mataix, Jorge; Nucci, Paolo; Sarraf, David; Giuliari, Gian Paolo; Albini, Thomas A.

In: Retina, Vol. 34, No. 10, 12.10.2014, p. 2044-2052.

Research output: Contribution to journalArticle

Kozak, I, Mansour, A, Diaz, RI, Calzada, JI, Pichi, F, Cruz-Villegas, V, Diaz-Llopis, M, Chhablani, J, Martinez-Cartier, M, Meerhoff, M, Mieler, WF, Arevalo, JF, Al Kahtani, E, Ghazi, N, Nowilaty, S, Al Rashaed, S, Al-Dhibi, HA, Al-Zahrani, YA, Gupta, V, Al-Kahtani, SA, Al-Marzoog, NA, Al-Robaie, AS, Al-Sulaiman, S, Al-Abdullah, A, Al-Bar, A, Al-Dhafiri, Y, Al-Qahtani, A, Al-Rubaie, K, Al-Shahrani, S, Al-Shehri, M, Younis, M, Heriot, W, Hall, A, Mackensen, F, Ziemssen, F, Mercé, E, Anand, R, Ahmadieh, H, Mataix, J, Nucci, P, Sarraf, D, Giuliari, GP & Albini, TA 2014, 'Outcomes of treatment of pediatric choroidal neovascularization with intravitreal antiangiogenic agents: The results of the KKESH international collaborative retina study group', Retina, vol. 34, no. 10, pp. 2044-2052. https://doi.org/10.1097/IAE.0000000000000200
Kozak, Igor ; Mansour, Ahmad ; Diaz, Rocio I. ; Calzada, Jorge I. ; Pichi, Francesco ; Cruz-Villegas, Vanessa ; Diaz-Llopis, Manuel ; Chhablani, Jay ; Martinez-Cartier, Mauricio ; Meerhoff, Martin ; Mieler, William F. ; Arevalo, J Fernando ; Al Kahtani, Eman ; Ghazi, Nicola ; Nowilaty, Sawsan ; Al Rashaed, Saba ; Al-Dhibi, Hassan A. ; Al-Zahrani, Yahya A. ; Gupta, Vishali ; Al-Kahtani, Sultan Ahmad ; Al-Marzoog, Naif Abdullah ; Al-Robaie, Abdullah Saad ; Al-Sulaiman, Sulaiman ; Al-Abdullah, Abdulelah ; Al-Bar, Ahmad ; Al-Dhafiri, Yousef ; Al-Qahtani, Abdullah ; Al-Rubaie, Khalid ; Al-Shahrani, Saeed ; Al-Shehri, Maha ; Younis, Muhammad ; Heriot, Wilson ; Hall, Anthony ; Mackensen, Friederike ; Ziemssen, Focke ; Mercé, Emilie ; Anand, Rajiv ; Ahmadieh, Hamid ; Mataix, Jorge ; Nucci, Paolo ; Sarraf, David ; Giuliari, Gian Paolo ; Albini, Thomas A. / Outcomes of treatment of pediatric choroidal neovascularization with intravitreal antiangiogenic agents : The results of the KKESH international collaborative retina study group. In: Retina. 2014 ; Vol. 34, No. 10. pp. 2044-2052.
@article{584f288e84854d4ea840a0f8453b68a4,
title = "Outcomes of treatment of pediatric choroidal neovascularization with intravitreal antiangiogenic agents: The results of the KKESH international collaborative retina study group",
abstract = "PURPOSE:: To evaluate safety and clinical results of intravitreal antiangiogenic agents for choroidal neovascularization in pediatric patients. METHODS:: Retrospective, multicenter, interventional case series. A total of 45 eyes of 39 pediatric patients with choroidal neovascularization of various etiologies were treated with intravitreal injection of antiangiogenic agents (1.25 mg per 0.05 mL of bevacizumab or 0.5 mg per 0.05 mL of ranibizumab). RESULTS:: There were 24 girls and 15 boys with group median age of 13 years (range, 3-17 years). Mean follow-up period was 12.8 months (range, 3-60 months). Median visual acuity in terms of logarithm of the minimum angle of resolution at presentation and last follow-up was 0.87 and 0.7, respectively (P = 0.0003). Mean and median number of injections received over the follow-up period was 2.2 and 1, respectively. At the last follow-up, 22 eyes (48{\%}) gained more than 3 lines of vision and 27 eyes (60{\%}) had final visual acuity 20/50 or better. Nine eyes (20{\%}) did not improve and had severe vision loss (20/200 or worse). CONCLUSION:: Intravitreal antiangiogenic therapy for choroidal neovascularization in pediatric patients seems temporarily safe and effective in majority of affected eyes. Because of the rarity and character of this condition, it is unlikely that any clinical trials will soon take place to study this or other treatment option.",
keywords = "antiangiogenic therapy, children, choroidal neovascularization",
author = "Igor Kozak and Ahmad Mansour and Diaz, {Rocio I.} and Calzada, {Jorge I.} and Francesco Pichi and Vanessa Cruz-Villegas and Manuel Diaz-Llopis and Jay Chhablani and Mauricio Martinez-Cartier and Martin Meerhoff and Mieler, {William F.} and Arevalo, {J Fernando} and {Al Kahtani}, Eman and Nicola Ghazi and Sawsan Nowilaty and {Al Rashaed}, Saba and Al-Dhibi, {Hassan A.} and Al-Zahrani, {Yahya A.} and Vishali Gupta and Al-Kahtani, {Sultan Ahmad} and Al-Marzoog, {Naif Abdullah} and Al-Robaie, {Abdullah Saad} and Sulaiman Al-Sulaiman and Abdulelah Al-Abdullah and Ahmad Al-Bar and Yousef Al-Dhafiri and Abdullah Al-Qahtani and Khalid Al-Rubaie and Saeed Al-Shahrani and Maha Al-Shehri and Muhammad Younis and Wilson Heriot and Anthony Hall and Friederike Mackensen and Focke Ziemssen and Emilie Merc{\'e} and Rajiv Anand and Hamid Ahmadieh and Jorge Mataix and Paolo Nucci and David Sarraf and Giuliari, {Gian Paolo} and Albini, {Thomas A.}",
year = "2014",
month = "10",
day = "12",
doi = "10.1097/IAE.0000000000000200",
language = "English (US)",
volume = "34",
pages = "2044--2052",
journal = "Retina",
issn = "0275-004X",
publisher = "Lippincott Williams and Wilkins",
number = "10",

}

TY - JOUR

T1 - Outcomes of treatment of pediatric choroidal neovascularization with intravitreal antiangiogenic agents

T2 - The results of the KKESH international collaborative retina study group

AU - Kozak, Igor

AU - Mansour, Ahmad

AU - Diaz, Rocio I.

AU - Calzada, Jorge I.

AU - Pichi, Francesco

AU - Cruz-Villegas, Vanessa

AU - Diaz-Llopis, Manuel

AU - Chhablani, Jay

AU - Martinez-Cartier, Mauricio

AU - Meerhoff, Martin

AU - Mieler, William F.

AU - Arevalo, J Fernando

AU - Al Kahtani, Eman

AU - Ghazi, Nicola

AU - Nowilaty, Sawsan

AU - Al Rashaed, Saba

AU - Al-Dhibi, Hassan A.

AU - Al-Zahrani, Yahya A.

AU - Gupta, Vishali

AU - Al-Kahtani, Sultan Ahmad

AU - Al-Marzoog, Naif Abdullah

AU - Al-Robaie, Abdullah Saad

AU - Al-Sulaiman, Sulaiman

AU - Al-Abdullah, Abdulelah

AU - Al-Bar, Ahmad

AU - Al-Dhafiri, Yousef

AU - Al-Qahtani, Abdullah

AU - Al-Rubaie, Khalid

AU - Al-Shahrani, Saeed

AU - Al-Shehri, Maha

AU - Younis, Muhammad

AU - Heriot, Wilson

AU - Hall, Anthony

AU - Mackensen, Friederike

AU - Ziemssen, Focke

AU - Mercé, Emilie

AU - Anand, Rajiv

AU - Ahmadieh, Hamid

AU - Mataix, Jorge

AU - Nucci, Paolo

AU - Sarraf, David

AU - Giuliari, Gian Paolo

AU - Albini, Thomas A.

PY - 2014/10/12

Y1 - 2014/10/12

N2 - PURPOSE:: To evaluate safety and clinical results of intravitreal antiangiogenic agents for choroidal neovascularization in pediatric patients. METHODS:: Retrospective, multicenter, interventional case series. A total of 45 eyes of 39 pediatric patients with choroidal neovascularization of various etiologies were treated with intravitreal injection of antiangiogenic agents (1.25 mg per 0.05 mL of bevacizumab or 0.5 mg per 0.05 mL of ranibizumab). RESULTS:: There were 24 girls and 15 boys with group median age of 13 years (range, 3-17 years). Mean follow-up period was 12.8 months (range, 3-60 months). Median visual acuity in terms of logarithm of the minimum angle of resolution at presentation and last follow-up was 0.87 and 0.7, respectively (P = 0.0003). Mean and median number of injections received over the follow-up period was 2.2 and 1, respectively. At the last follow-up, 22 eyes (48%) gained more than 3 lines of vision and 27 eyes (60%) had final visual acuity 20/50 or better. Nine eyes (20%) did not improve and had severe vision loss (20/200 or worse). CONCLUSION:: Intravitreal antiangiogenic therapy for choroidal neovascularization in pediatric patients seems temporarily safe and effective in majority of affected eyes. Because of the rarity and character of this condition, it is unlikely that any clinical trials will soon take place to study this or other treatment option.

AB - PURPOSE:: To evaluate safety and clinical results of intravitreal antiangiogenic agents for choroidal neovascularization in pediatric patients. METHODS:: Retrospective, multicenter, interventional case series. A total of 45 eyes of 39 pediatric patients with choroidal neovascularization of various etiologies were treated with intravitreal injection of antiangiogenic agents (1.25 mg per 0.05 mL of bevacizumab or 0.5 mg per 0.05 mL of ranibizumab). RESULTS:: There were 24 girls and 15 boys with group median age of 13 years (range, 3-17 years). Mean follow-up period was 12.8 months (range, 3-60 months). Median visual acuity in terms of logarithm of the minimum angle of resolution at presentation and last follow-up was 0.87 and 0.7, respectively (P = 0.0003). Mean and median number of injections received over the follow-up period was 2.2 and 1, respectively. At the last follow-up, 22 eyes (48%) gained more than 3 lines of vision and 27 eyes (60%) had final visual acuity 20/50 or better. Nine eyes (20%) did not improve and had severe vision loss (20/200 or worse). CONCLUSION:: Intravitreal antiangiogenic therapy for choroidal neovascularization in pediatric patients seems temporarily safe and effective in majority of affected eyes. Because of the rarity and character of this condition, it is unlikely that any clinical trials will soon take place to study this or other treatment option.

KW - antiangiogenic therapy

KW - children

KW - choroidal neovascularization

UR - http://www.scopus.com/inward/record.url?scp=84925286376&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84925286376&partnerID=8YFLogxK

U2 - 10.1097/IAE.0000000000000200

DO - 10.1097/IAE.0000000000000200

M3 - Article

VL - 34

SP - 2044

EP - 2052

JO - Retina

JF - Retina

SN - 0275-004X

IS - 10

ER -